Selective inhibitor of transforming growth factor-β
type I receptor (ALK5), ALK4 and ALK7 (IC50
values are 47 and 129 nM for ALK5 and ALK4 respectively). Selectively inhibits signaling from TGF-β
and activin; does not inhibit other ALK family members.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7.
Byfield et al.
Reactive oxygen species production via NADPH oxidase mediates TGF-β-induced cytoskeletal alterations in endothelial cells.
Hu et al.
Am.J.Physiol.Renal Physiol., 2005;289:F816
The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis.
Noma et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 505124 include:
2 Citations: Showing 1 - 2